公开(公告)号：US08986954B2

公开(公告)日：2015-03-24

申请号：US14285721

申请日：2014-05-23

Applicant: UCB Pharma S.A.

Inventor： Helene Margaret Finney ,  Terence Seward Baker ,  Alastair David Griffiths Lawson ,  Karen Margrete Miller ,  Marc Roger de Ryck ,  Christian Gilbert J. Wolff

IPC: C07H21/04 ,  C12P21/08 ,  C12N5/10 ,  C07K16/18 ,  C07K16/28

CPC classification number: C07K16/28 ,  A61K39/3955 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76

Abstract: A Nav1.7 binding entity that after binding functionally modifies the activity of the ion channel, in particular an anti-Nav1.7 antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.

Abstract translation: 结合后的Nav1.7结合实体功能性地修饰离子通道的活性，特别是抗Nav1.7抗体或其结合片段，包含所述抗体的药物组合物，使用抗体及其组合物在治疗中 ，例如在疼痛的治疗/调节中以及产生和制备所述抗体的方法。

公开(公告)号：US20140342406A1

公开(公告)日：2014-11-20

申请号：US14285721

申请日：2014-05-23

Applicant: UCB PHARMA S.A.

Inventor： Helene Margaret Finney ,  Terence Seward Baker ,  Alastair David Griffiths Lawson ,  Karen Margrete Miller ,  Marc Roger de Ryck ,  Christian Gilbert J. Wolff

IPC: C07K16/28

CPC classification number: C07K16/28 ,  A61K39/3955 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76

Abstract: A Nav1.7 binding entity that after binding functionally modifies the activity of the ion channel, in particular an anti-Nav1.7 antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.

Abstract translation: 结合后的Nav1.7结合实体功能性地修饰离子通道的活性，特别是抗Nav1.7抗体或其结合片段，包含所述抗体的药物组合物，使用抗体及其组合物在治疗中 ，例如在疼痛的治疗/调节中以及产生和制备所述抗体的方法。